about
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalActivity of 2,4-diaminoquinazoline compounds against Candida species5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study.The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid.Fungal retinitis: a case of Torulopsis glabrata infection treated with miconazole.Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephrSerious infectious complications after flexible fiberoptic bronchoscopy.In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.Use and safety of antimicrobial agents during pregnancy.Chemotherapy of experimental endogenous Candida albicans endophthalmitis.The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Management of mycoses in neutropenic patients: a brief history, 1960-2008Antifungal therapy: from amphotericin B to present.Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora.Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States.5-fluorocytosine susceptibility of pathogenic fungi in the presence of allopurinol: potential for improving the therapeutic index of 5-fluorocytosineSkeletal cryptococcosis: Case report and review of the literature.Pharmacokinetics of antifungal agents in children.Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity.Antifungal research strategies aiming for new targets.Development of proteomics-based fungicides: new strategies for environmentally friendly control of fungal plant diseases.The use of antifungal therapy in neonatal intensive care.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Antifungal agents and liver toxicity: a complex interaction.Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association.Recent developments in the supportive therapy of acute myelogenous leukemia.The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans.Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole.Improved procedure for determination of flucytosine in human blood plasma by high-pressure liquid chromatography.Combined activity of ketoconazole and 5-fluorocytosine on potentially pathogenic yeasts.Candida infection in surgical patients.Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.Rapid determination of serum 5-fluorocytosine levels by high-performance liquid chromatographyShort-term curative treatment of Aspergillus fumigatus pneumonia with fluconazole.Drug-induced alterations in serum creatinine concentrations.Managing infections in immunosuppressed patients.Chromomycosis. Successful treatment with 5-fluorocytosine.Hydrogen-bonding patterns in 5-fluoro-cytosine-melamine co-crystal (4/1).Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.Intracranial infection in cardiac transplant recipients.
P2860
Q27012487-B1CE369C-F47C-4D4D-9666-54B67195829CQ28325786-6CFC75AE-2561-4CBC-8DC5-1283458F81C3Q33341541-29CBF31F-DD3A-46F2-914D-19267503EFD0Q33612121-7A32E6DC-9EA7-4ED9-AE37-4138167C9239Q33652112-12A8BBE0-5611-4B01-B322-52639D5976B3Q33978188-A4513BC9-E6A2-4CEC-A6AB-582448C5D874Q34107709-8CD82364-3AD4-4A09-87DE-9FDBEA41E3D5Q34142406-C9037DFC-78D6-4B60-A16F-711DE397B991Q34195656-2945C5D7-343F-46A0-8F94-E6E41FDCBA60Q34211724-9132D633-DB86-43D5-BF2A-89D5DF60F874Q35127510-7E38A83B-BBFA-48E6-BF8E-557DD80AC123Q35245371-215899F9-E04E-46B6-AFD5-9A9003A518DBQ35648327-F7F731E8-E810-491A-9816-652068216C2DQ35716914-77770BB5-9985-4A52-9426-5296B899613FQ35754645-9BAC9547-7B24-4833-933A-9DF7ADE63F90Q35891417-C70D2440-440B-4040-8400-2DC3D9DFDC9AQ36163345-2A1D3399-1555-4DCA-89A9-E0A42BF01D54Q36476427-4CD8C546-1972-48F2-8CF0-B40D7E283359Q37588637-38233F7C-507C-47A3-9D3E-D3EC5F2F4FAEQ37845680-74AE100B-C2BB-486C-83E1-096D2476B91CQ37985070-6A67ACD8-17CB-41B5-9DBF-AA166456F311Q38193337-EB079FD8-40EB-4637-BD50-A44CB92CF5FBQ38816614-06DF4088-7106-4E70-9D0B-FEBBDA204BC9Q38858839-A7C9865B-2082-46A6-9703-297F8AE7EE44Q38876936-B33DD50A-A83B-4761-ABDE-AF71CA431D1EQ39207564-179A03DB-4786-436F-9A83-EA8ED56C5337Q39685110-83F9C275-239C-4EA2-8EAE-549C05251B73Q39779579-8C8AD711-E132-4ED3-9FFF-247B29819533Q39833449-9ACB13CD-7D3C-493B-8BED-55BE8B747F8DQ39856578-B9C280E0-193F-4547-9028-40C71633F608Q40306552-1A16DF63-C4B6-464F-B12A-B682E3F3EDCCQ40330676-D320622C-5573-4D3A-9052-7819EA8EE364Q40471113-A036AC37-D749-4126-9FD5-7257D4B3ADAFQ40766804-2950BB58-1D24-4611-B64A-2F92961666D9Q40832838-729161AB-6FA3-4395-8133-1C159046A438Q40873919-79D1EDAA-98DD-4C0E-8C13-AC402AB88ABCQ41566423-1EABC513-3285-4798-9CEB-504559F17783Q41838182-726BB527-16DC-4615-AC5F-4B366D69B884Q42129126-DB582609-4819-40EF-93A5-9959102874C3Q44183285-52F75B94-AA6C-4AAF-8A51-75432A564857
P2860
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Flucytosine.
@en
Flucytosine.
@nl
type
label
Flucytosine.
@en
Flucytosine.
@nl
prefLabel
Flucytosine.
@en
Flucytosine.
@nl
P1476
Flucytosine.
@en
P2093
P304
P356
10.7326/0003-4819-86-3-319
P407
P577
1977-03-01T00:00:00Z